Compositions and methods for inhibiting leishmania

Patent metadata

Field	Value
Publication number	US-2016120844-A1
Application number	US-201514924605-A
Country	US
Kind code	A1
Filing date	Oct 27, 2015
Priority date	Oct 30, 2014
Publication date	May 5, 2016
Grant date	—

Abstract

Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts.

First claim

What is claimed as new and desired to be protected by Letters Patent of the United States is:

1 . A method of reducing the LDU of Leishmaniasis in a host, comprising:
administering an AI to the host wherein the LDU of Leishmaniasis in the host of Leishmaniasis is reduced.

2 . The method of claim 1 , wherein the LDU is reduced by reduced to less than about 47% of the untreated control.

3 . The method of claim 1 , wherein the AI is AR-12.

4 . The method of claim 1 , wherein the AI is co-administered with a second compound.

5 . The method of claim 1 , wherein the second compound is selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole.

6 . The method of claim 5 , wherein the resulting parasite burden is less than about 1% of the untreated control

7 . A method treating a host infected with Leishmaniasis, comprising:
administering a daily dose of at least about 0.1 mg/kg of a AI and a second compound to the host.

8 . The method of claim 7 , wherein the AI is AR-12.

9 . The method of claim 7 , wherein the second compound is selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole.

10 . A composition comprising an AI, amphotericin B, and a pharmaceutically acceptable carrier.

11 . The composition of claim 10 , wherein the AI is AR-12.

12 . The composition of claim 11 , further comprising a compound selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole.

13 . A composition comprising an AI, SSG, and a pharmaceutically acceptable carrier.

14 . The composition of claim 13 , wherein the AI is AR-12.

Assignees

• Ohio State Innovation Foundation

Inventors

• Ainslie Kristy
• Bachelder Eric
• Gautam Shalini
• Peine Kevin
• Satoskar Abhay

Classifications

• A61K31/415 Primary

  1,2-Diazoles · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title